Citations

Mayo Clinic

Showing 10 of 108585 citations.

Bad to worse: mitral regurgitation increases from moderate–severe to torrential following cardioversion to sinus rhythm
Shipman, Justin , Alsidawi, Said , Alsidawi, Said , Srivathsan, Komandoor

European Heart Journal - Cardiovascular Imaging | October 7, 2023 | Volume: 25 | Issue: 1 | Pages: e63-e63

10.1093/ehjci/jead253 | PMID 37804530 Get It

The Third Annual Symposium of the Midwest Aging Consortium
Keller, Andrea , Eliazer, Susan , Hansen, Malene , Konopka, Adam R. , Morales‐Nebreda, Luisa , Najt, Charles P. , Prahlad, Veena , Victorelli, Stella , Yuan, Rong , Rhoads, Timothy W. , Konopka, Adam R , Vorland, Colby J , Rhoads, Timothy W , Morales-Nebreda, Luisa C , Bai, Hua , Budinger, G. R. Scott , Mihaylova, Maria M.

The Journals of Gerontology: Series A | October 7, 2023 | Volume: 79 | Issue: 2 | Pages: No page available

10.1093/gerona/glad239 | PMID 37804247 Get It

Abstract The geroscience hypothesis suggests that addressing the fundamental mechanisms driving aging biology will prevent or mitigate the onset of multiple chronic diseases, for which the largest risk factor is advanced age. Research that investigates the root causes of aging is therefore of critical importance given the rising healthcare burden attributable to age-related diseases. The third annual Midwest Aging Consortium symposium was convened as a showcase of such research performed by investigators from institutions across the Midwestern United States. This report summarizes the work presented during a virtual conference across topics in aging biology, including immune function in the lung—particularly timely given the Corona Virus Immune Disease-2019 pandemic—along with the role of metabolism and nutrient-regulated pathways in cellular function with age, the influence of senescence on stem cell function and inflammation, and our evolving understanding of the mechanisms underlying observation of sex dimorphism in aging-related outcomes. The symposium focused on early-stage and emerging investigators, while including keynote presentations from leaders in the biology of aging field, highlighting the diversity and strength of aging research in the Midwest.
Trends in Cardiovascular Disease Mortality by County‐Level Social Vulnerability Index in the United States
Terry, Katrina, Makhlouf, Mohamed H. E. , Altarabsheh, Salah E. , Petermann‐Rocha, Fanny , Elgudin, Yakov , Nasir, Khurram , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Deo, Salil V. , Makhlouf, Mohamed , Elgudin, Yakov , Nasir, Khurram , Rajagopalan, Sanjay , Al-Kindi, Sadeer , Deo, Salil , Altarabsheh, Salah , Deo, Vaishali Salil

Journal of the American Heart Association | October 7, 2023 | Volume: 12 | Issue: 20 | Pages: No page available

10.1161/jaha.123.030290 | PMID 37804196 Get It

Background Although cardiovascular mortality (CVM) rates in the United States have been declining overall, our study evaluated whether this holds true for areas with increased social deprivation. Methods and Results We used county‐level cross‐sectional age‐adjusted CVM rates (aa‐CVM) (2000–2019) linked to the Centers for Disease Control and Prevention Social Vulnerability Index (SVI–2010). We grouped counties as per SVI (Groups I 0–0.2, II 0.21–0.4, III 0.41–0.6, IV 0.61–0.8, and V 0.81–1) and calculated the relative change in the aa‐CVM between 2000 to 2003 and 2016 to 2019. We used adjusted linear regression analyses to explore the association between a higher SVI and temporal aa‐CVM improvement; we studied this temporal change in aa‐CVM across subgroups of race, sex, and location. The median aa‐CVM rate (per 100 000) was 272.6 (interquartile range [IQR]: 237.5–311.7). The aa‐CVM was higher in men (315.6 [IQR: 273.4–363.9]) than women (221.3 [IQR: 189.6–256.7]), and in Black residents (347.2 [IQR: 301.1–391.1]; P <0.001) than White residents (258.9 [IQR: 226–299.1]; P <0.001). The aa‐CVM for SVI I (233.6 [IQR: 214.8–257.0]) was significantly lower than that of group V (323.6 [IQR: 277.2–359.2]; P <0.001). The relative reduction in CVM was significantly higher for SVI group I (32.2% [IQR: 24.2–38.4]) than group V (27.2% [IQR: 19–34.1]) counties. After multivariable adjustment, a higher SVI index was associated with lower relative improvement in the age‐adjusted CVM (model coefficient −3.11 [95% CI, −5.66 to −1.22]; P <0.001). Conclusions Socially deprived counties in the United States had higher aa‐CVM rates, and the improvement in aa‐CVM over the past 20 years was lower in these counties.
Broncholithiasis
Reid, Michal , Mullon, John J., Mullon, John

New England Journal of Medicine | October 7, 2023 | Volume: 389 | Issue: 15 | Pages: No page available

10.1056/nejmicm2206122 | PMID 37815211 Get It

Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, Jeyeon , Burkett, Brian J. , Min, Hoon‐Ki , Dicks, Ellen , Corriveau‐Lecavalier, Nick , Mester, Carly , Wiste, Heather J. , Murray, Melissa E. , Nguyen, Aivi T. , Reichard, Ross R., Graff‐Radford, Jonathan , Barnard, Leland R , Gunter, Jeffrey L. , Kantarci, Kejal , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Corriveau-Lecavalier, Nick , Mester, Carly T, Lundt, Emily S. , Murray, Melissa E , Botha, Hugo , Graff-Radford, Jonathan , Schwarz, Christopher G , Kantarci, Kejal , Knopman, David S. , Boeve, Brad , Jack, Clifford R , Jones, David T , Min, Hoon-Ki Paul , Nguyen, Aivi T , Burkett, Brian , Senjem, Matthew L. , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Jones, David T.

Brain | October 7, 2023 | Volume: 147 | Issue: 3 | Pages: 980-995

10.1093/brain/awad346 | PMID 37804318 Get It

Abstract Given the prevalence of dementia and the development of pathology-specific disease-modifying therapies, high-value biomarker strategies to inform medical decision-making are critical. In vivo tau-PET is an ideal target as a biomarker for Alzheimer’s disease diagnosis and treatment outcome measure. However, tau-PET is not currently widely accessible to patients compared to other neuroimaging methods. In this study, we present a convolutional neural network (CNN) model that imputes tau-PET images from more widely available cross-modality imaging inputs. Participants (n = 1192) with brain T1-weighted MRI (T1w), fluorodeoxyglucose (FDG)-PET, amyloid-PET and tau-PET were included. We found that a CNN model can impute tau-PET images with high accuracy, the highest being for the FDG-based model followed by amyloid-PET and T1w. In testing implications of artificial intelligence-imputed tau-PET, only the FDG-based model showed a significant improvement of performance in classifying tau positivity and diagnostic groups compared to the original input data, suggesting that application of the model could enhance the utility of the metabolic images. The interpretability experiment revealed that the FDG- and T1w-based models utilized the non-local input from physically remote regions of interest to estimate the tau-PET, but this was not the case for the Pittsburgh compound B-based model. This implies that the model can learn the distinct biological relationship between FDG-PET, T1w and tau-PET from the relationship between amyloid-PET and tau-PET. Our study suggests that extending neuroimaging’s use with artificial intelligence to predict protein specific pathologies has great potential to inform emerging care models.
Association Between Whole Blood–Derived Mitochondrial DNA Copy Number, Low‐Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk
Liu, Xue , Sun, Xianbang, Jiang, Wenqing , Lai, M M , Wiggins, Kerri L. , Raffield, Laura M. , Bielak, Lawrence F. , Zhao, Wei , Pitsillides, Achilleas , Haessler, Jeffrey, Blackwell, Thomas W. , Yao, Jie , Qian, Yong , Thyagarajan, Bharat , Peyser, Patricia A. , Heckbert, Susan R. , Seshadri, Sudha , Boerwinkle, Eric , Grove, Megan L. , Larson, Nicholas B. , Smith, Jennifer A. , Fitzpatrick, Annette L., Fornage, Myriam , Ding, Jun , Carson, April P. , Reiner, Alex P. , Hou, Lifang , Wilson, James G. , Rotter, Jerome I. , Bis, Joshua C. , Arking, Dan E. , Zhao, Wei , Wiggins, Kerri L , Raffield, Laura M , Bielak, Lawrence F , Zhao, Wei , Pitsillides, Achilleas , Zheng, Yinan , Yao, Jie , Guo, Xiuqing , Thyagarajan, Bharat , Pankratz, Nathan , Rich, Stephen S , Taylor, Kent D , Peyser, Patricia A , Heckbert, Susan R , Boerwinkle, Eric , Larson, Nicholas B , Smith, Jennifer A , Vasan, Ramachandran S , Fornage, Myriam , Carson, April P , Dupuis, Josée , Reiner, Alexander P , Hou, Lifang , Psaty, Bruce M , Levy, Daniel , Rotter, Jerome I , Bis, Joshua C , Satizabal, Claudia L , Arking, Dan E , Liu, Chunyu , Seshadri, Sudha , Zhang, Yuankai , Zheng, Yinan , Guo, Xiuqing , Pankratz, Nathan , Rich, Stephen S. , Taylor, Kent D. , Vasan, Ramachandran S. , Abecasis, Gonçalo R. , Kooperberg, Charles , Psaty, Bruce M. , Levy, Daniel , Satizábal, Claudia L.

Journal of the American Heart Association | October 7, 2023 | Volume: 12 | Issue: 20 | Pages: No page available

10.1161/jaha.122.029090 | PMID 37804200 Get It

Background The relationship between mitochondrial DNA copy number (mtDNA CN) and cardiovascular disease remains elusive. Methods and Results We performed cross‐sectional and prospective association analyses of blood‐derived mtDNA CN and cardiovascular disease outcomes in 27 316 participants in 8 cohorts of multiple racial and ethnic groups with whole‐genome sequencing. We also performed Mendelian randomization to explore causal relationships of mtDNA CN with coronary heart disease (CHD) and cardiometabolic risk factors (obesity, diabetes, hypertension, and hyperlipidemia). P <0.01 was used for significance. We validated most of the previously reported associations between mtDNA CN and cardiovascular disease outcomes. For example, 1‐SD unit lower level of mtDNA CN was associated with 1.08 (95% CI, 1.04–1.12; P <0.001) times the hazard for developing incident CHD, adjusting for covariates. Mendelian randomization analyses showed no causal effect from a lower level of mtDNA CN to a higher CHD risk (β=0.091; P =0.11) or in the reverse direction (β=−0.012; P =0.076). Additional bidirectional Mendelian randomization analyses revealed that low‐density lipoprotein cholesterol had a causal effect on mtDNA CN (β=−0.084; P <0.001), but the reverse direction was not significant ( P =0.059). No causal associations were observed between mtDNA CN and obesity, diabetes, and hypertension, in either direction. Multivariable Mendelian randomization analyses showed no causal effect of CHD on mtDNA CN, controlling for low‐density lipoprotein cholesterol level ( P =0.52), whereas there was a strong direct causal effect of higher low‐density lipoprotein cholesterol on lower mtDNA CN, adjusting for CHD status (β=−0.092; P <0.001). Conclusions Our findings indicate that high low‐density lipoprotein cholesterol may underlie the complex relationships between mtDNA CN and vascular atherosclerosis.
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race
Schmeusser, Benjamin N. , Patil, Dattatraya , Nicaise, Edouard , Armas‐Phan, Manuel , Nabavizadeh, Reza , Narayan, Vikram M. , Joshi, Shreyas , Ogan, Kenneth , Osunkoya, Adeboye O. , Bilen, Mehmet Asım , Master, Viraj A. , Patil, Dattatraya H , Nicaise, Edouard H , Joshi, Shreyas S , Bilen, Mehmet A , Narayan, Vikram M

Cancer | October 7, 2023 | Volume: 130 | Issue: 3 | Pages: 453-466

10.1002/cncr.35037 | PMID 37803521 Get It

AbstractBackgroundThe 2018 Leibovich prognostic model for nonmetastatic renal cell carcinoma (RCC) combines clinical, surgical, and pathologic factors to predict progression‐free survival (PFS) and cancer‐specific survival (CSS) for patients with clear cell (ccRCC), papillary (pRCC), and chromophobe (chRCC) histology. Despite high accuracy, <1% of the original cohort was Black. Here, the authors examined this model in a large population with greater Black patient representation.MethodsBy using a prospectively maintained RCC institutional database, patients were assigned Leibovich model risk scores. Survival outcomes included 5‐year and 10‐year PFS and CSS. Prognostic accuracy was determined using area under the curve (AUC) analysis and calibration plots. Black patient subanalyses were conducted.ResultsIn total, 657 (29%) of 2295 patients analyzed identified as Black. Declines in PFS and CSS were observed as scores increased. Discrimination for ccRCC was strong for PFS (AUC: 5‐year PFS, 0.81; 10‐year PFS, 0.78) and for CSS (AUC: 5‐year CSS, 0.82; 10‐year CSS, 0.74). The pRCC AUC for PFS was 0.74 at 5 years and 0.71 at 10 years; and the AUC for CSS was 0.74 at 5 years and 0.70 at 10 years. In chRCC, better performance was observed for CSS (AUC at 5 years, 0.75) than for PFS (AUC: 0.66 at 5 years; 0.55 at 10 years). Black patient subanalysis revealed similar‐to‐improved performance for ccRCC at 5 years (AUC: PFS, 0.79; CSS, 0.87). For pRCC, performance was lower for PFS (AUC at 5 years, 0.63) and was similar for CSS (AUC at 5 years, 0.77). Sample size limited Black patient 10‐year and chRCC analyses.ConclusionsThe authors externally validated the 2018 Leibovich RCC prognostic model and found optimal performance for ccRCC, followed by pRCC, and then chRCC. Importantly, the results were consistent in this large representation of Black patients.Plain Language Summary In 2018, a model to predict survival in patients with renal cell carcinoma (kidney cancer) was introduced by Leibovich et al. This model has performed well; however, Black patients have been under‐represented in examination of its performance. In this study, 657 Black patients (29%) were included, and the results were consistent. This work is important for making sure the model can be applied to all patient populations.
The association of thromboembolic complications and the use of tranexamic acid during resection of intracranial meningiomas: systematic review and meta-analysis of randomized controlled trials
Nguyen, Andrew , Brown, Nolan J. , Nguyen, Brandon A., Pennington, Zach , Chakravarti, Sachiv , Douse, Dontre’ M. , Pennington, Zach , Gendreau, Julian , Nguyen, Brandon , Zhang, Angie , Harris, Mark H. , Gompel, Jamie J. Van

Journal of Neurosurgery | October 7, 2023 | Volume: 140 | Issue: 4 | Pages: 1008-1018

10.3171/2023.7.jns23849 | PMID 37856372 Get It

OBJECTIVE Antifibrinolytics, such as tranexamic acid (TXA), have been shown to decrease intraoperative blood loss across multiple surgical disciplines. However, they carry the theoretical risk of thromboembolic events secondary to induced hypercoagulability. Therefore, the aim of this study was to systematically review the available literature and perform a meta-analysis on the use of TXA in meningioma resection to assess thromboembolic risks. METHODS The PubMed, Web of Science, and Google Scholar databases were reviewed for all randomized controlled trials presenting primary data on TXA use during resection of intracranial meningiomas. Data were gathered on operative duration, venous thromboembolic complications, deep venous thrombosis, use of allogeneic blood transfusion, estimated blood loss (EBL), and postoperative hemoglobin. Patients who received TXA were compared with controls who did not receive TXA intraoperatively using random-effects models. RESULTS A total of 508 unique articles were identified, of which 493 underwent full-text review. Ultimately, 6 studies with 381 total patients (190 receiving TXA) were included in the final analysis. All 6 trials were randomized, blinded, and placebo controlled with a TXA administration rate of a 20-mg/kg load followed by a 1-mg/kg/hr infusion. All studies were performed in lower-middle-income countries. There were no reported instances of venous thromboembolism (VTE) in the TXA and non-TXA cohorts. Patients receiving TXA exhibited fewer allogeneic transfusions (21.5% vs 41.6% [OR 0.26, 95% CI 0.09–0.77], p = 0.02) and lower EBL (MD −282.48 mL [95% CI −367.77 to −197.20 mL], p < 0.001) compared with patients who did not receive TXA, and they also had lower rates of perioperative complications (10.7% vs 19.9% [OR 0.47, 95% CI 0.2–0.95], p = 0.04). CONCLUSIONS Current literature suggests that TXA is not associated with increased risk for VTE when administered during resection of intracranial meningioma. TXA appears to decrease intraoperative blood loss and allogeneic transfusion requirements during meningioma resection and thus may improve the safety of surgical management of this pathology.
Healthcare disparities in deep brain stimulation access and utilization: a systematic review
Deshpande, Nachiket , Hadi, Moustafa, Ali, Rushna

Journal of Neurosurgery | October 7, 2023 | Volume: 140 | Issue: 4 | Pages: 1137-1147

10.3171/2023.7.jns23277 | PMID 38240596 Get It

OBJECTIVE Since FDA approval of deep brain stimulation (DBS) for essential tremor over 2 decades ago, indications and utilization of this modality have rapidly expanded worldwide. However, certain patient populations are known to be underrepresented among those undergoing DBS for various indications. METHODS A systematic search was conducted using PubMed and Embase for disparities related to DBS care. Any retrospective or prospective study addressing inequalities related to DBS were included for qualitative analysis. Additionally, all clinical trials and DBS studies with at least 100 patients were also included to evaluate for demographic disparities in the DBS literature. RESULTS Of the 5192 screened articles, 43 were included. The authors found that female gender, minority race, geographic barriers, low socioeconomic status, and the presence of multiple comorbidities are all linked to the underutilization of DBS. Analysis of demographic data from large-scale DBS studies and clinical trials revealed that females and Black patients continue to be underrepresented in the DBS literature and among those receiving DBS therapy. CONCLUSIONS As the indications and utilization continue to grow, addressing healthcare disparities related to DBS has become increasingly important. The authors suggest that increasing patient and provider education, expanding the role of telemedicine within DBS care, and improving support services for DBS patients may improve access and utilization.
Editorial. Who, or what, to believe
Link, Michael J., Carlson, Matthew L. , Link, Michael J.

Journal of Neurosurgery | October 7, 2023 | Volume: 140 | Issue: 4 | Pages: 1038-1040

10.3171/2023.8.jns231656 | PMID 37856376 Get It